Last reviewed · How we verify

FEX60/PE10 — Competitive Intelligence Brief

FEX60/PE10 (FEX60/PE10) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine/decongestant combination. Area: Allergy/Immunology.

phase 3 Antihistamine/decongestant combination H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine) Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

FEX60/PE10 (FEX60/PE10) — Sanofi. FEX60/PE10 is a fixed-dose combination of fexofenadine (a selective H1-receptor antagonist) and pseudoephedrine (a sympathomimetic decongestant) that reduces allergic symptoms and nasal congestion.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
FEX60/PE10 TARGET FEX60/PE10 Sanofi phase 3 Antihistamine/decongestant combination H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine)
Coristina d Coristina d Brainfarma Industria Química e Farmacêutica S/A phase 3 Antihistamine/Decongestant combination H1 histamine receptor; alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine/decongestant combination class)

  1. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FEX60/PE10 — Competitive Intelligence Brief. https://druglandscape.com/ci/fex60-pe10. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: